Mabpharm Limited (HK:2181) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mabpharm Limited has announced the early termination of a tenancy agreement between its subsidiary Biomabs and Shengheng Biotech, initially set to end in December 2024. The termination agreement allows Shengheng Biotech to vacate the premises by September 30, 2024, and is considered beneficial for the Group as it coincides with Biomabs’ new business developments and the securing of a more favorable lease nearby. The decision was made in the interest of the shareholders and the Group, following arm’s length negotiations.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.